Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received an average recommendation of “Hold” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $166.00.
A number of equities research analysts have issued reports on JAZZ shares. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price for the company. in a research note on Friday, September 13th. ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Oppenheimer set a $176.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, November 11th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total transaction of $65,000.00. Following the completion of the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at approximately $40,541,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.
Shares of NASDAQ:JAZZ traded up $0.28 during trading on Friday, reaching $138.90. 603,909 shares of the company traded hands, compared to its average volume of 550,265. The firm has a fifty day simple moving average of $125.83 and a 200 day simple moving average of $131.94. The firm has a market cap of $7.84 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 1.08 and a beta of 1.09. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $154.44. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.19 by $0.91. The company had revenue of $537.70 million during the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter last year, the business posted $3.58 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals will post 14.15 EPS for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: How to calculate the annual rate of depreciation
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.